Incannex reports positive Phase 2 results for PSX-001 in Generalized Anxiety Disorder

Incannex Healthcare Inc.

Psi-GAD (PSX-001) achieved a 12.8-point HAM-A reduction vs. 3.6 for placebo (p<0.0001) over 11 weeks.
44.1% of patients had clinical response (≥50% HAM-A reduction) and 27% achieved full remission (HAM-A ≤7).
GAD-7 scores fell 7.4 points, SDS improved 6.0 points, PHQ-9 dropped 3.9 points, all statistically significant.
No serious adverse events reported; only one subject withdrew from the 73-participant trial.
Incannex plans a multi-jurisdiction Phase 2 trial and is exploring strategic partnerships for PSX-001.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.